Investigating immune cells in liver cancer among HIV-infected patients
Tumor-associated pDC (TApDC) in liver cancer with HIV infection
This study is looking at how certain immune cells behave in liver cancer patients who also have HIV, with the goal of creating better treatments for liver cancer, especially for those in African American and immigrant communities. If you join this research, you could help find new ways to boost your immune system against cancer while reducing side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Maryland Baltimore NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11083935 on NIH RePORTER |
What this research studies
This research focuses on understanding how tumor-associated plasmacytoid dendritic cells (TApDC) function within the immune environment of liver cancer, particularly in patients who are also living with HIV. The study aims to develop new treatments for hepatocellular carcinoma (HCC) that disproportionately affects African American and African/Asian immigrant communities. By exploring the effects of immunotherapy and the role of immune checkpoint inhibitors, the research seeks to enhance anti-tumor immunity while minimizing adverse effects. Patients participating in this research may contribute to the development of more effective therapies tailored to their unique health challenges.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with liver cancer who are also living with HIV, particularly those from African American and African/Asian immigrant backgrounds.
Not a fit: Patients without liver cancer or those who are not HIV-infected may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for liver cancer in HIV-infected patients, enhancing their quality of life and survival rates.
How similar studies have performed: Previous research has shown promise in using immune checkpoint inhibitors for cancer treatment, indicating potential success for this novel approach in the context of HIV and liver cancer.
Where this research is happening
Baltimore, United States
- University of Maryland Baltimore — Baltimore, United States (Active)
Researchers
- Principal investigator: Su, Lishan — University of Maryland Baltimore
- Study coordinator: Su, Lishan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.